The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
he application is supported by data from the Phase 3 MANGROVE trial. The trial met its primary endpoint of progression-free survival, showing that the combination reduced the risk of disease progression or death compared to standard chemoimmunotherapy.
In the first video of an MDS case study series, Guillermo García-Manero, MD, discusses the diagnosis and treatment of a 72-year-old woman presenting with anemia.
The chemotherapy-free oral regimen showed both central nervous system penetration and activity across ABL1 mutants, supporting its potential for this high-risk pediatric patient population, wrote the study’s authors, led by Jinlia Zhang, DM, of the Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
The analysis, led by Jennifer J Huang, MD, PhD, of Fred Hutchinson Cancer Center of University of Washington in Seattle, was presented at the Fourteenth Annual Meeting of the Society of Hematologic Oncology in Houston, Texas.
Ann LaCasce, MD, MMSc, took an unexpected path to becoming a lymphoma specialist. After someone stole her organic chemistry notebook in college, she traded pre-med for the art world, spending five years working in a contemporary art gallery before returning to medicine
Data from the trial, led by Elias Jabbour, MD, of The University of Texas MD Anderson Cancer Center, were presented at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois.
SOHO Insider is the official media platform of the Society of Hematologic Oncology. The SOHO Insider Editorial Board is comprised of leading hematologists. Learn more about our editorial board and SOHO Insider platforms.
To access the SOHO Career Center click the following link.
